Optimum Investment Advisors reduced its stake in Shire PLC (NASDAQ:SHPG) by 21.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,174 shares of the biopharmaceutical company’s stock after selling 604 shares during the quarter. Optimum Investment Advisors’ holdings in Shire PLC were worth $359,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Hartford Financial Management Inc. lifted its position in Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 32 shares during the last quarter. YorkBridge Wealth Partners LLC boosted its holdings in shares of Shire PLC by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 317 shares during the period. Pacer Advisors Inc. bought a new stake in shares of Shire PLC during the second quarter worth approximately $171,000. Stephens Inc. AR bought a new stake in shares of Shire PLC during the first quarter worth approximately $179,000. Finally, Quantbot Technologies LP bought a new stake in shares of Shire PLC during the first quarter worth approximately $182,000. 19.28% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Shire PLC (NASDAQ:SHPG) traded up 0.14% during mid-day trading on Tuesday, hitting $153.35. The company had a trading volume of 215,071 shares. Shire PLC has a one year low of $139.36 and a one year high of $198.58.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, analysts forecast that Shire PLC will post $14.93 EPS for the current year.

The firm also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s payout ratio is 41.07%.

SHPG has been the subject of several research reports. Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the stock a “hold” rating in a report on Wednesday, July 26th. ValuEngine lowered Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research cut Shire PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub cut Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Royal Bank Of Canada set a $213.00 target price on Shire PLC and gave the stock a “buy” rating in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have issued a buy rating to the company. Shire PLC has a consensus rating of “Buy” and an average price target of $220.08.

COPYRIGHT VIOLATION WARNING: “Optimum Investment Advisors Decreases Position in Shire PLC (SHPG)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/03/optimum-investment-advisors-decreases-position-in-shire-plc-shpg.html.

Shire PLC Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.